Last updated: 11/07/2018 13:48:28
A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder.
Trial description: A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Ballenger JC et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder; Am. J. Psychiatry 1998; 155:36-42.
Paroxetine in the short- and long-term treatment of panic disorder. Gergel, I, Bushnell, W D, and Burnham, D B 21st Collegium Internationale Neuro-Psychopharmacologicum Congress (CINP '98) 7/12/1998 Glasgow; Scotland
Medical condition
Panic Disorder
Product
paroxetine
Collaborators
Not applicable
Study date(s)
September 1992 to April 1994
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1994-01-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website